Navigation Links
Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics

Three Oritavancin Studies Presented at ECCMID/ICC

MUNICH, Germany, April 03, 2007 /PRNewswire/ -- Targanta Therapeutics today announced results from two studies showing the improved potency of oritavancin to stop bacterial growth in vitro when tested with a common wetting agent (polysorbate 80) and one study demonstrating the activity of oritavancin against S. pneumoniae in a mouse model of pneumonia. Oritavancin, a novel lipoglycopeptide antibiotic, is Targanta's lead product currently in post- Phase 3 clinical development. These findings were presented at the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 25th International Congress of Chemotherapy (ICC) in Munich, Germany from March 31 - April 3, 2007.

"We are encouraged by the research demonstrating the improved activity of oritavancin when compared with other glycopeptide antibiotics. By combining oritavancin with a common wetting agent, it is evident that the ability of the treatment to inhibit bacteria growth, demonstrated through previous research, may be underestimated based on these recent studies," said Thomas Parr, Ph.D., Chief Scientific Officer, Targanta Therapeutics. "These data further support oritavancin as a potential treatment for serious bacterial infections, and Targanta will continue to explore this potential through ongoing clinical research."

    The following research was presented at the ECCMID/ICC meeting:

      --  Effect of polysorbate 80 on oritavancin binding to plastic surfaces

          -- implications for susceptibility testing (ECCMID/ICC07-P 1112)

      --  Influence of polysorbate 80 on susceptibility of gram-positive

          bacteria to oritavancin (ECCMID/ICC07-P 827)

      --  Efficacy of oritavancin in a mouse model of Streptococcus pneumoniae

          pneumonia (ECCMID/ICC07-P 1781)


    Study Methods and Results:

    --  Effect of polysorbate 80 on oritavancin binding to plastic surfaces --

        implic
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:6/2/2015)... , June 2, 2015  BD (Becton, ... leading global medical technology company, today announced its ... Stewardship and outlined multiple steps the company will ... "BD has a full range of expertise ... from diagnosis and treatment information to electronic surveillance ...
(Date:6/2/2015)... Thync today launched the first consumer ... feeling more calm or energized when you need it most. ... simple wearable is placed on the head and designed for ... device is operated with an accompanying app to deliver Thync ... level. "Our mission at Thync is to ...
(Date:6/2/2015)... MADRID , June 2, 2015 ... 10503) effectuée lors de la réunion annuelle de ... PharmaMar communique que Janssen Research & Development, LLC ... multicentrique de phase III SAR3007 qui démontrent une ... avec la trabectédine (YONDELIS ® ) comparé à ...
Breaking Medicine Technology:BD Participates in White House Forum on Antibiotic Stewardship 2BD Participates in White House Forum on Antibiotic Stewardship 3Thync Launches First Wearable to Shift Your State of Mind 2Thync Launches First Wearable to Shift Your State of Mind 3Thync Launches First Wearable to Shift Your State of Mind 4PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 2PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 3PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 4PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 5PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 6
(Date:6/2/2015)... 2015 Shimadzu Scientific Instruments today ... mass spectrometer. The newest model in the Ultra-Fast ... proprietary ultrafast technologies (UF technologies) with new ion ... data quality and higher throughput for a wide ... LCMS-8060 features new technology, including a stronger vacuum ...
(Date:6/2/2015)... Recent findings from the 2014 ... has been a reduction in conventional cigarette smoking, use ... (hookah) usage has doubled among today’s teens in a ... believes the national trend is consistent with what is ... 20 years to fully determine the long-term effects of ...
(Date:6/2/2015)... June 02, 2015 ODU ... high performance connector solutions and cable assemblies, is ... solutions to the US market. , ODU ... locking capabilities. The self- securing circular connector solution ... applications that require significant customization such as: sensor ...
(Date:6/2/2015)... Jersey (PRWEB) June 02, 2015 ... largest nonprofit provider of home health care, hospice ... its President and CEO, Steve Landers, MD, MPH, ... Board of Directors. , VNAA is a ... promotes and advances mission driven, nonprofit providers of ...
(Date:6/2/2015)... TheCelebrityDresses.com, a popular online store selling celebrity ... summer fashion cocktail dresses. The company carries more than ... be suitable for a wide variety of summer events ... and make high quality trendy special occasion dresses ... quality satin, chiffon and cotton. Their products feature a ...
Breaking Medicine News(10 mins):Health News:Shimadzu’s New LC-MS/MS Provides Superior Speed and Sensitivity for the Utmost in Quantitative Detection and High-Speed Analysis 2Health News:Susquehanna Health Pediatrician Warns of Adverse Effects of Teen E-Cigarette Usage 2Health News:Susquehanna Health Pediatrician Warns of Adverse Effects of Teen E-Cigarette Usage 3Health News:ODU Announces ODU MINI-SNAP® - Advanced Circular Connector Solution for Highly Customizable Applications 2Health News:Steve Landers, MD, MPH, President and CEO of VNA Health Group Appointed to VNAA Board of Directors 2Health News:Steve Landers, MD, MPH, President and CEO of VNA Health Group Appointed to VNAA Board of Directors 3
... , , SUFFIELD, Conn. ... , a leading national provider of nutritional products and services exclusive ... Corporate Headquarters and East Coast Distribution Center from East Windsor, ... Suffield, Connecticut . , The move accommodates continued growth, enabling ...
... , WASHINGTON , Feb. 4 ... Institute for Legal Reform (ILR), made the following statement on ... the state,s medical malpractice law: , (Logo: http://www.newscom.com/cgi-bin/prnh/20080919/USCHAMBERLOGO ) ... another blow to the state,s reputation as a haven for ...
... , WASHINGTON , Feb. 4 The ... quarter ended December 31, 2009 , the third quarter of its fiscal ... to $60.9 million , from $59.3 million in the quarter ... million as of December 31, 2009 , up from $230.9 ...
... , TACOMA, Wash. , Feb. 4 ... possible by the Food and Drug Administration (FDA) for adhering to ... Mammography Quality Standards Act (MQSA).  Receiving the "All Items in Compliance" ... U.S. breast programs have not received this high quality standard.   ...
... , Feb. 4 The American Heart Association estimates ... type of cardiovascular disease. Many of those people will die of ... Super Bowl or World Cup where the tension and stress levels ... attacks in 2002 and 2001, doctors in Switzerland found ...
... second leading cause of cancer-related deaths in the United States. ... this disease, rates of screening for colorectal cancer are consistently ... and cervical. Although the screening rates in the target population ... in 1997 to nearly 55 percent in 2008 the ...
Cached Medicine News:Health News:Designs for Health Expands into New Corporate Headquarters 2Health News:Designs for Health Expands into New Corporate Headquarters 3Health News:Striking Down Medical Liability Reforms Another Blow to Illinois' Poor Lawsuit Climate 2Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 2Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 3Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 4Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 5Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 6Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 7Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 8Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 9Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 10Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 11Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 12Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 13Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 14Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 15Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 16Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 17Health News:The Advisory Board Company Reports Results For Quarter Ended 12/31/09 18Health News:Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 3Health News:Panel calls for reducing colorectal cancer deaths by striking down barriers to screening 2
... monitoring for flexible care settings., ... combine portability and measurement flexibility to ... of intermediate care environmentsat the patients ... heritage in patient monitoring, IntelliVue has ...
... information gathering and distribution power of the ... option of connecting the MPC workstations to ... The OCU is essentially a database driven ... central clearinghouse for patient information acquired from ...
... Vital Signs Monitor 300 Series enhances your ... during and after procedures. This easy to ... sign readings fast and convenient., ,The ... a noninvasive blood pressure monitor with the ...
... original Welch Allyn Vital Signs ... for clinical areas that don't ... straightforward to use, each monitor ... pressure, and optional features include ...
Medicine Products: